<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1626">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139992</url>
  </required_header>
  <id_info>
    <org_study_id>ASH RC CTN 2021-00001</org_study_id>
    <nct_id>NCT05139992</nct_id>
  </id_info>
  <brief_title>COVID-19 Vaccine Response in Sickle Cell Disease</brief_title>
  <official_title>COVID-19 Vaccine Response in People Living With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASH Research Collaborative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society of Hematology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ASH Research Collaborative</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the antibody response to COVID-19 vaccination in a&#xD;
      cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related&#xD;
      complications around the time of vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sickle cell disease (SCD) is a genetic disorder caused by a single base substitution of&#xD;
      valine for a glutamine at the sixth amino acid of the gene encoding for the hemoglobin Î²&#xD;
      chain. Patients with Hgb SS disease and other sickle hemoglobinopathies suffer from a variety&#xD;
      of clinical complications related to this abnormal hemoglobin. These clinical manifestations&#xD;
      include hemolytic anemia, painful vaso-occlusive crisis, and end organ damage. Persons with&#xD;
      SCD generally auto-splenectomize in childhood secondary to infarctions from their&#xD;
      hemoglobinopathy, thus increasing their risk of infection and rendering them&#xD;
      immunosuppressed. Data suggest that general immune function in SCD patients may be impaired,&#xD;
      and thus responses to vaccine may be suboptimal.&#xD;
&#xD;
      Patients with SCD are considered at increased risk of complications from infection from&#xD;
      SARS-CoV-2 infection and are therefore an important group to receive vaccination against the&#xD;
      virus. Understanding response to COVID-19 vaccination is this high-risk group of patients can&#xD;
      provide a more targeted approach to vaccination in order to achieve adequate protection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody response to COVID-19 vaccine in persons with sickle cell disease</measure>
    <time_frame>2 months post initial vaccination</time_frame>
    <description>IgG ELISA based antibody titer to SARS-CoV-2 spike RBD antigen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody response to COVID-19 vaccine in persons with sickle cell disease</measure>
    <time_frame>6 months post initial vaccination</time_frame>
    <description>IgG ELISA based antibody titer to SARS-CoV-2 spike RBD antigen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of vaccination and sickle cell related complications around the time of vaccination</measure>
    <time_frame>2-3 days post vaccination, 2 months post vaccination, 6 months post vaccination</time_frame>
    <description>Assessed by questionnaire and medical record review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patient reported COVID-19 infections</measure>
    <time_frame>Within 6 months following vaccination</time_frame>
    <description>Patient report</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Observational Cohort</arm_group_label>
    <description>Previously unvaccinated persons with sickle cell disease who are scheduled to receive their initial COVID-19 vaccine series.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Vaccine</intervention_name>
    <description>Vaccination against SARS-CoV-2</description>
    <arm_group_label>Observational Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 200 subjects with sickle cell disease will be enrolled at up to 20 sites&#xD;
        participating in the ASH RC Sickle Cell Disease Clinical Trials Network.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+ thalassemia,&#xD;
             HbS/Other)&#xD;
&#xD;
          2. Has not received any COVID-19 vaccination prior to enrollment&#xD;
&#xD;
          3. Scheduled for a COVID-19 vaccination (type does not matter) as part of routine&#xD;
             clinical care&#xD;
&#xD;
          4. Willing and able to sign consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwilling to have labs drawn or complete study requirements.&#xD;
&#xD;
          2. Previous therapy curative of SCD (including bone marrow transplant and gene therapy)&#xD;
&#xD;
          3. Previous receipt of anti-COVID-19 antibody therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Abrams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie Lanzkron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Mortier</last_name>
    <phone>202-292-6005</phone>
    <email>nmortier@ashrc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Regine Hyppolite</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Manuela Plazas Montana</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Karen Ireland</last_name>
    </contact>
    <contact_backup>
      <last_name>Jenai Jackson</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dana Thompson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prisma Health - Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tranaka Fuqua</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lorraine Burkhalter</last_name>
    </contact>
    <contact_backup>
      <last_name>Stephanie Reyes</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

